Pacific Edge Ltd: Annual Report 2024

Jun 26 18:54 ET · Announcements

Pacific Edge FY2024 Operating Revenue Jumps 22% to NZ$23.9 Million, Total Revenue Rises 12% to NZ$29.3 Million

Cancer diagnostics company Pacific Edge (NZE:PEB, ASX:PEB) said operating revenue rose 22% to NZ$23.9 million and total revenue increased 12% to NZ$29.3 million for the year ended March, according to

MT NewswiresMay 21 17:44 ET

Pacific Edge Revenues Up, Cash Costs Down on Reorganisation

Cancer diagnostic pharmaceutical company Pacific Edge Ltd (ASX:PEB) has reported a drop of 24 percent in cash costs in the second half of the Financial Year, based on a reorganisation of the company, in addition to revenue growth throughout the year ahead of its chairman Chris Gallaher stepping down.

The Market HeraldMay 20 20:06 ET

Pacific Edge Ltd: Cash Burn Slows Coverage Catalysts in Focus

May 20 17:31 ET · Announcements

Pacific Edge Reports Steady Growth in Bladder Cancer Test Volumes in Fiscal Q4

Pacific Edge's (ASX:PEB, NZE:PEB) test volumes for its Cxbladder product rose 0.4% to 7,210 in the fiscal fourth quarter ended March 31, compared with the prior three-month period, the cancer diagnost

MT NewswiresApr 8 23:06 ET

New Zealand Shares Flat on Thursday; Pacific Edge's Chair to Retire

New Zealand shares were flat with a negative bias at Thursday's close, dragged down by the shares of firms in the heavyweight finance sector. The S&P/NZX 50 Index was little changed to close at 11,808

MT NewswiresMar 14 00:41 ET